MSD

News

Histopathological image representing a bone marrow aspirate in a patient with essential thrombocythemia

MSD starts second phase 3 of Imago drug for blood cancers

MSD has kicked off a new phase 3 trial of its oral LSD1 inhibitor bomedemstat in essential thrombocythaemia (ET), one of a rare type of blood cancer known as myeloproliferative neoplasms (M

News

With FDA okay, AZ takes on MSD in early-stage lung cancer

AstraZeneca has claimed FDA approval for its immunotherapy Imfinzi before and after surgery for non-small cell lung cancer, setting up a contest with MSD's rival Keytruda.

News

MSD adds bispecific cancer antibody via $1.3bn Curon deal

MSD has an extensive pipeline in oncology but hasn't been a player in bispecific antibodies.

News

Person with their hand covering their face

More bad news for TIGIT as MSD stops another trial

Another TIGIT trial failure has been abandoned, casting a shadow once again over the target as a cancer immunotherapy strategy.

News

MSD, Daiichi Sankyo lung cancer ADC starts phase 3

One of three antibody-drug conjugates licensed by MSD for $4 billion upfront last year has started phase 3 testing in a form of lung cancer.

News

MSD stakes claim to RSV prevention market for infants

MSD has reported phase 2b/3 data with its clesrovimab antibody for respiratory syncytial virus (RSV) preventions in infants, which could be a challenger to Sanofi and AstraZeneca's fast-gro

MSD starts second phase 3 of Imago drug for blood cancers

With FDA okay, AZ takes on MSD in early-stage lung cancer

MSD adds bispecific cancer antibody via $1.3bn Curon deal

More bad news for TIGIT as MSD stops another trial

MSD, Daiichi Sankyo lung cancer ADC starts phase 3

MSD stakes claim to RSV prevention market for infants

Repligen builds in cell therapy with $1.5bn BioLife takeover

Discover a new era of healthcare panel engagement: Grounded ...

MSD

Editor's Picks